Chemed Corporation (CHE) Stock Forecast
Data as of Oct 31, 2026Healthcare · Current price $536.03 (-1.09%)
Price Target Range
Consensus Price Target Over Time
Analyst Rating Distribution
Last 3 Months
6-Month Trend
Latest Analyst Forecasts
Price targets issued by Wall Street analysts. Upside calculated against today's price.
| Date | Analyst | Firm | Price Target | Upside |
|---|---|---|---|---|
| Jan 22, 2026 | Brian Tanquilut | Jefferies | $475.00 | -11.4% |
| Nov 5, 2024 | Frank Morgan | RBC Capital | $633.00 | +18.1% |
| May 21, 2024 | Frank Morgan | RBC Capital | $697.00 | +30.0% |
Top Analysts Covering CHE
CHE vs Sector & Market
| Metric | CHE | Healthcare Avg | Large Cap Avg |
|---|---|---|---|
| Analyst Rating | 2.43 | 2.25 | 2.41 |
| Analyst Count | 7 | 8 | 19 |
| Target Upside | +18.5% | +153002.0% | +21.5% |
| P/E Ratio | 29.20 | 3.44 | 38.49 |
Revenue Estimates
| Period | Low | Avg | High | # |
|---|---|---|---|---|
| 2026-12-31 | $688M | $690M | $693M | 3 |
| 2027-03-31 | $697M | $700M | $703M | 3 |
| 2027-06-30 | $702M | $705M | $707M | 2 |
| 2027-09-30 | $709M | $712M | $715M | 2 |
| 2027-12-31 | $735M | $738M | $741M | 3 |
| 2028-12-31 | $3.00B | $3.01B | $3.02B | 1 |
EPS Estimates
| Period | Low | Avg | High | # |
|---|---|---|---|---|
| 2026-12-31 | $7.14 | $7.18 | $7.22 | 2 |
| 2027-03-31 | $6.14 | $6.17 | $6.21 | 2 |
| 2027-06-30 | $6.19 | $6.22 | $6.25 | 1 |
| 2027-09-30 | $6.38 | $6.41 | $6.44 | 1 |
| 2027-12-31 | $7.53 | $7.57 | $7.61 | 2 |
| 2028-12-31 | $28.75 | $28.90 | $29.06 | 1 |
Frequently Asked Questions
What is the analyst consensus for CHE?
The consensus among 7 analysts covering Chemed Corporation (CHE) is Buy with an average price target of $650.00.
What is the highest price target for CHE?
The highest price target for CHE is $697.00, set by Frank Morgan at RBC Capital on 2024-05-21.
What is the lowest price target for CHE?
The lowest price target for CHE is $475.00, set by Brian Tanquilut at Jefferies on 2026-01-22.
How many analysts cover CHE?
7 analysts have issued ratings for Chemed Corporation in the past 12 months.
Is CHE a buy or sell right now?
Based on 7 analyst ratings, CHE has a consensus rating of Buy (2.43/5) with a +18.5% upside to the consensus target of $650.00.
What are the earnings estimates for CHE?
Analysts estimate CHE will report EPS of $7.18 for the period ending 2026-12-31, with revenue estimated at $690M.
Related Stock Forecasts
Data updated daily. Analyst price targets sourced from public filings and broker reports. Not investment advice.